Scott Haden Kollins

Scott Haden Kollins

Adjunct Professor in the Department of Psychiatry and Behavioral Sciences

External Address: 
2608 Erwin Road Lakeview Pavi, Durham, NC 27705
Internal Office Address: 
Box 3527 Med Ctr, Durham, NC 27710


Scott H. Kollins, PhD received his undergraduate degree in psychology from Duke and his Master’s and Doctorate degrees in Clinical Psychology from Auburn University. After completing his clinical internship at the University of Mississippi Medical Center, where he served as Chief Intern, he joined the faculty of the Department of Psychology at Western Michigan University for three years, before joining the Duke faculty in 2000. Dr. Kollins has published more than 125 scientific papers in peer-reviewed journals.  Over the past 10 years, his research has been supported by 6 different federal agencies, including NICHD, NIDA, NIMH, NIEHS, NINDS, and EPA, and he currently holds a mid-career K24 award from NIDA.  He has also served as PI on more than 40 industry-funded clinical trials and is a consultant to a number of pharmaceutical companies in the area of ADHD clinical psychopharmacology.  He has served as a standing member of the Child Psychopathology and Developmental Disabilities study section and also served as an ad-hoc reviewer for 10 additional NIH study sections and 7 international granting agencies. He is an Associate Editor for the Journal of Attention Disorders and has reviewed for more than 50 different peer-reviewed journals. He is an elected member of the College on Problems of Drug Dependence and the American College of Neuropsychopharmacology. Dr. Kollins is a licensed clinical psychologist and maintains a practice through the ADHD Program’s outpatient clinic. His research interests are in the areas of psychopharmacology and the intersection of ADHD and substance abuse, particularly cigarette smoking.

Education & Training

  • Ph.D., Auburn University 1997

Selected Grants

SEP-225289 in Adults with Attention Deficit Hyperactivity Disorder (ADHD) awarded by Sunovion Pharmaceuticals, Inc (Principal Investigator). 2014 to 2016


Friis-Healy, Elsa A., et al. “It Is Time to REACT: Opportunities for Digital Mental Health Apps to Reduce Mental Health Disparities in Racially and Ethnically Minoritized Groups.Jmir Ment Health, vol. 8, no. 1, Jan. 2021, p. e25456. Pubmed, doi:10.2196/25456. Full Text

Mitchell, John T., et al. “Sluggish cognitive tempo (SCT) in an adult outpatient sample seeking an attention-deficit/hyperactivity disorder assessment: Age of onset and assessment method impact on SCT rates.J Psychiatr Res, vol. 131, Dec. 2020, pp. 203–08. Pubmed, doi:10.1016/j.jpsychires.2020.09.013. Full Text

Engelhard, Matthew M., et al. “Health system utilization before age 1 among children later diagnosed with autism or ADHD.Sci Rep, vol. 10, no. 1, Oct. 2020, p. 17677. Pubmed, doi:10.1038/s41598-020-74458-2. Full Text

Adjei, Akwete L., et al. “A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR®) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder.Paediatr Drugs, vol. 22, no. 5, Oct. 2020, pp. 561–70. Pubmed, doi:10.1007/s40272-020-00409-z. Full Text

Lunsford-Avery, Jessica R., et al. “Feasibility and Acceptability of Wearable Sleep Electroencephalogram Device Use in Adolescents: Observational Study.Jmir Mhealth Uhealth, vol. 8, no. 10, Oct. 2020, p. e20590. Pubmed, doi:10.2196/20590. Full Text

Fuemmeler, Bernard F., et al. “Associations between attention deficit hyperactivity disorder symptoms and eating behaviors in early childhood.Pediatr Obes, vol. 15, no. 7, July 2020, p. e12631. Pubmed, doi:10.1111/ijpo.12631. Full Text

Childress, Ann C., et al. “Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder.J Child Adolesc Psychopharmacol, vol. 30, no. 3, Apr. 2020, pp. 128–36. Pubmed, doi:10.1089/cap.2019.0117. Full Text

Kollins, Scott H., et al. “A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial.Lancet Digit Health, vol. 2, no. 4, Apr. 2020, pp. e168–78. Pubmed, doi:10.1016/S2589-7500(20)30017-0. Full Text


Witt, K. L., et al. “Chromosomal aberrations, sister chromatid exchanges, and micronuclei in lymphocytes of pediatric ADHD patients treated with stimulant drugs.” Environmental and Molecular Mutagenesis, vol. 49, no. 7, WILEY-BLACKWELL, 2008, pp. 528–528.

Goodman, D., et al. “Efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.” International Journal of Neuropsychopharmacology, vol. 11, CAMBRIDGE UNIV PRESS, 2008, pp. 292–93.

Kollins, Scott, et al. “Genetic associations with reaction time variability in AD/HD.” American Journal of Medical Genetics Part B Neuropsychiatric Genetics, vol. 141B, no. 7, WILEY-LISS, 2006, pp. 771–72.

Schug, M. D., et al. “The genetics of AD/HD: Subtyping, comorbidity and developmental considerations.” American Journal of Medical Genetics Part B Neuropsychiatric Genetics, vol. 130B, no. 1, WILEY-LISS, 2004, pp. 103–103.